We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie aujourd’hui son calendrier financier pour l’année 2025 : 27 mars 2025 : Publication...
IPH6501 est un NK Cell Engager tetra-spécifique de nouvelle génération, comprenant un variant de l’IL-2, ciblant CD20 et développé dans les lymphomes non Hodgkiniens à cellules B. IPH6501...
Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related...
Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que de nouvelles données précliniques soutenant le développement...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.176 | -10.8910891089 | 1.616 | 1.62 | 1.398 | 69692 | 1.45200906 | DE |
4 | -0.288 | -16.6666666667 | 1.728 | 1.738 | 1.39 | 90509 | 1.53188509 | DE |
12 | -0.61 | -29.756097561 | 2.05 | 2.19 | 1.39 | 72003 | 1.75309308 | DE |
26 | -1.23 | -46.0674157303 | 2.67 | 2.765 | 1.39 | 60039 | 1.94323046 | DE |
52 | -0.87 | -37.6623376623 | 2.31 | 2.8 | 1.39 | 75776 | 2.23077997 | DE |
156 | -2.86 | -66.511627907 | 4.3 | 4.84 | 1.39 | 143515 | 2.91959217 | DE |
260 | -4.34 | -75.0865051903 | 5.78 | 7.48 | 1.39 | 251909 | 3.94507346 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions